Business
Novo Nordisk's Forecast Update Fails to Persuade Investors
Novo Nordisk’s raised forecast on its obesity business failed to convince Wall Street of a sustainable growth path amid intensifying competition from Eli Lilly.
Coverage timeline — 1 article
CNBC
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
2026-08-05 06:11 UTC